Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Single Arm Trial Testing the ZN-c3 WEE1 Inhibitor in Combination With Gemcitabine in Second-Line Advanced Pancreatic Adenocarcinoma

NCT06015659 is registered in ClinicalTrials.gov with Brandon Huffman, MD as lead sponsor.

NCT NCT06015659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06015659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Single Arm Trial Testing the ZN-c3 WEE1 Inhibitor in Combination With Gemcitabine in Second-Line Advanced Pancreatic Adenocarcinoma
Lead sponsor
Brandon Huffman, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 16, 2023
Completion date
June 1, 2027
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic adenocarcinoma, pancreatic cancer, pancreatic ductal adenocarcinoma